Search results for "Signal"

showing 10 items of 6924 documents

Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome

2017

// Mariona Jove 1, * , Irene Pradas 1, * , Alba Naudi 1, * , Susana Rovira-Llopis 2 , Celia Banuls 2 , Milagros Rocha 2 , Manuel Portero-Otin 1 , Antonio Hernandez-Mijares 2, 3, 4, # , Victor M. Victor 2, 5, # and Reinald Pamplona 1, # 1 Department of Experimental Medicine, Lleida University-Institute for Research in Biomedicine of Lleida (UdL-IRBLleida), 25198 Lleida, Spain 2 Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Service of Endocrinology, University Hospital Dr. Peset, 46017 Valencia, Spain 3 Fundacion Investigacion Hospital Clinico Universitario/INCLIVA, Valencia University, 46010 Valencia, Spain 4 Department of Medicine, …

0301 basic medicineOncologyCell signaling moleculesmedicine.medical_specialtyCell signalingGlycerophospholipidsDiseaseGlycerophospholipidsFree fatty acidsValencian community03 medical and health sciences0302 clinical medicineInternal medicineLipidomicsmedicinelipid de novo biosynthesisglycerophospholipids030219 obstetrics & reproductive medicinebusiness.industryfree fatty acidsLipidomeUniversity hospitalPolycystic ovary030104 developmental biologyOncologyLipidomicscell signaling moleculeslipidomicsbusinessResearch PaperOncotarget
researchProduct

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.

2017

We investigated PD-L1 changes in response to MEK and AKT inhibitors in KRAS mutant lung adenocarcinoma (adeno-NSCLC). PD-L1 expression was quantified using immunofluorescence and co-culture with a jurkat cell-line transfected with NFAT-luciferase was used to study if changes in PD-L1 expression in cancer cell lines were functionally relevant. Five KRAS mutant cell lines with high PD-L1 expression (H441, H2291, H23, H2030 and A549) were exposed to GI50 inhibitor concentrations of a MEK inhibitor (trametinib) and an AKT inhibitor (AZD5363) for 3 weeks. Only 3/5 (H23, H2030 and A549) and 2/5 cell lines (H441 and H23) showed functionally significant increases in PD-L1 expression when exposed to…

0301 basic medicineOncologyCell signalingLung NeoplasmsLuminescenceImmunofluorescenceMutantCancer Treatmentlcsh:MedicineSignal transductionERK signaling cascademedicine.disease_causeJurkat cellsB7-H1 AntigenLung and Intrathoracic TumorsMajor Histocompatibility ComplexWhite Blood Cells0302 clinical medicineAnimal CellsCarcinoma Non-Small-Cell LungMedicine and Health Scienceslcsh:ScienceTrametinibMultidisciplinarymedicine.diagnostic_testT CellsChemistryPhysicsElectromagnetic RadiationMEK inhibitorSignaling cascadesOncology030220 oncology & carcinogenesisPhysical SciencesKRASCellular TypesResearch Articlemedicine.medical_specialtyGeneral Science & TechnologyImmune CellsImmunologyResearch and Analysis MethodsImmunofluorescenceFluorescence03 medical and health sciencesCell Line TumorInternal medicineMD MultidisciplinarymedicineHumansImmunoassaysBlood Cellslcsh:RCancers and NeoplasmsBiology and Life SciencesCell BiologyCoculture TechniquesNon-Small Cell Lung Cancerrespiratory tract diseasesGenes ras030104 developmental biologyCell cultureMutationImmunologic TechniquesCancer researchClinical ImmunologyCancer biomarkerslcsh:QClinical MedicinePLoS ONE
researchProduct

Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.

2017

// James A. McCubrey 1 , Timothy L. Fitzgerald 2 , Li V. Yang 3 , Kvin Lertpiriyapong 4 , Linda S. Steelman 1 , Stephen L. Abrams 1 , Giuseppe Montalto 5,6 , Melchiorre Cervello 6 , Luca M. Neri 7 , Lucio Cocco 8 , Alberto M. Martelli 8 , Piotr Laidler 9 , Joanna Dulinska-Litewka 9 , Dariusz Rakus 10 , Agnieszka Gizak 10 , Ferdinando Nicoletti 11 , Luca Falzone 11 , Saverio Candido 11 and Massimo Libra 11 1 Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, USA 2 Department of Surgery, Brody School of Medicine at East Carolina University, Greenville, NC, USA 3 Department of Internal Medicine, Hematology/Oncology Section, Brody Sc…

0301 basic medicineOncologyGerontologycancer stem cellsmedicine.medical_specialtyEpithelial-Mesenchymal TransitionReviewPI3KNO03 medical and health sciencesGlycogen Synthase Kinase 30302 clinical medicineCancer stem cellGSK-3Internal medicinemicroRNAmedicineAnimalsHumansPTENEpithelial–mesenchymal transitionProtein kinase BPI3K/AKT/mTOR pathwayGSK-3biologybusiness.industryAnimalCancer stem cellAktWnt signaling pathwayWnt/beta-cateninMicroRNAMicroRNAsGSK-3 cancer stem cells Wnt/beta-catenin PI3K Akt030104 developmental biologyOncology030220 oncology & carcinogenesisNeoplastic Stem Cellsbiology.proteinNeoplastic Stem CellAkt; GSK-3; PI3K; Wnt/beta-catenin; cancer stem cellsbusinessHumanSignal Transduction
researchProduct

Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma

2020

Contains fulltext : 235640.pdf (Publisher’s version ) (Closed access) Genome-wide association studies (GWAS) of esophageal adenocarcinoma (EAC) and its precursor, Barrett's esophagus (BE), have uncovered significant genetic components of risk, but most heritability remains unexplained. Targeted assessment of genetic variation in biologically relevant pathways using novel analytical approaches may identify missed susceptibility signals. Central obesity, a key BE/EAC risk factor, is linked to systemic inflammation, altered hormonal signaling and insulin-like growth factor (IGF) axis dysfunction. Here, we assessed IGF-related genetic variation and risk of BE and EAC. Principal component analys…

0301 basic medicineOncologyMaleCancer Researchmedicine.medical_specialtyEsophageal NeoplasmsMedizinSingle-nucleotide polymorphismGenome-wide association studyBiologyAdenocarcinomaPolymorphism Single NucleotideReceptor IGF Type 103 medical and health sciencesBarrett Esophagus0302 clinical medicineRisk FactorsSomatomedinsInternal medicineGenetic variationmedicineBiomarkers TumorSNPHumansGenetic Predisposition to DiseaseRisk factorGerm-Line MutationCancer Biomarkers and Molecular EpidemiologyInsulin-like growth factor 1 receptorGenetic associationAgedGeneral MedicineMiddle Agedmedicine.diseaseRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biology030220 oncology & carcinogenesisBarrett's esophagusFemaleHuman medicineCarrier ProteinsGenome-Wide Association StudySignal TransductionCarcinogenesis
researchProduct

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis

2016

Lung metastasis is the major cause of death in osteosarcoma patients. However, molecular mechanisms underlying this metastasis remain poorly understood. To identify key molecules related with pulmonary metastasis of pediatric osteosarcomas, we analyzed high-throughput miRNA expression in a cohort of 11 primary tumors and 15 lung metastases. Results were further validated with an independent cohort of 10 primary tumors and 6 metastases. In parallel, we performed immunohistochemical analysis of activated signaling pathways in 36 primary osteosarcomas. Only phospho-AKT associated with lower overall survival in primary tumors, supporting its role in osteosarcoma progression. CTNNB1 expression a…

0301 basic medicineOncologyMaleCancer ResearchmiR‐200cLung NeoplasmsCDH1MetastasisCohort Studies0302 clinical medicineCell MovementPhospho‐AKTPhosphorylationChildOsteosarcomabiologyGeneral MedicineArticlesCadherinsPrognosisPrimary tumorGene Expression Regulation Neoplasticmedicine.anatomical_structureLung metastasisOncology030220 oncology & carcinogenesisDisease ProgressionMolecular MedicineOsteosarcomaFemaleSignal Transductionmedicine.medical_specialtyAdolescentMesenchymal to epithelial transitionArticle03 medical and health sciencesYoung AdultAntigens CDInternal medicineCell Line TumormicroRNAGeneticsmedicineBiomarkers TumorHumansEpithelial–mesenchymal transitionCell ProliferationLungGene Expression ProfilingReproducibility of ResultsEpithelial CellsPediatric osteosarcomamedicine.diseaseSurvival AnalysisEnzyme ActivationMicroRNAs030104 developmental biologyTumor progressionbiology.proteinProto-Oncogene Proteins c-aktMolecular Oncology
researchProduct

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospectiv…

2017

Natural Killer cells (NK) are lymphocytes with the potential to recognize and lyse cells which escaped T-cell mediated lysis due to their aberrant HLA expression profiles. Killer cell immunoglobulin-like receptors (KIR) influence NK-cell activity by mediation of activating or inhibitory signals upon interaction with HLA-C (C1, C2) ligands. Therefore, absence of ligands for donor inhibitory KIRs following hematopoietic stem cell transplantation (HSCT) may have an influence on its outcome. Previous studies showed that C1 negative patients have a decreased HSCT outcome. Our study, based on a cohort of 200 C1-negative patients, confirmed these findings for the endpoints: overall survival (OS: H…

0301 basic medicineOncologyMaleMyeloidCell Transplantationmedicine.medical_treatmentlcsh:MedicineHematopoietic stem cell transplantationNK cellsLigandsCohort StudiesWhite Blood Cells0302 clinical medicineMathematical and Statistical TechniquesReceptors KIRCell SignalingComplement C1Animal CellsMedicine and Health SciencesBlood and Lymphatic System ProceduresMembrane Receptor SignalingReceptorlcsh:ScienceBone Marrow TransplantationMultidisciplinaryT CellsIncidence (epidemiology)Hematopoietic Stem Cell TransplantationMiddle AgedImmune Receptor Signaling3. Good healthKiller Cells Naturalmedicine.anatomical_structureTreatment OutcomeHematologic NeoplasmsCohortPhysical SciencesFemaleCellular TypesUnrelated DonorsStatistics (Mathematics)Research ArticleSignal TransductionAdultmedicine.medical_specialtyAdolescentImmune CellsImmunologySurgical and Invasive Medical ProceduresResearch and Analysis Methods03 medical and health sciencesYoung AdultInternal medicinemedicineConfidence IntervalsHumansClinical significanceddc:610Statistical MethodsAgedRetrospective StudiesTransplantationBlood Cellsbusiness.industrylcsh:RBiology and Life SciencesRetrospective cohort studyCell BiologyMultivariate analysis; Stem cell transplantation; T cells; Bone marrow transplantation; NK cells; Hematopoietic stem cell transplantation; Immune receptor signalingTransplantation030104 developmental biologyImmunologyMultivariate Analysislcsh:QbusinessMathematics030215 immunologyStem Cell TransplantationPLoS ONE
researchProduct

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

2018

The eighth annual conference of “Innovative therapy, monoclonal antibodies, and beyond” was held in Milan on Jan. 26, 2018, and hosted by Fondazione IRCCS–Istituto Nazionale dei Tumori (Fondazione IRCCS INT). The conference was divided into two main scientific sessions, of i) pre-clinical assays and novel biotargets, and ii) clinical translation, as well as a third session of presentations from young investigators, which focused on recent achievements within Fondazione IRCCS INT on immunotherapy and targeted therapies. Presentations in the first session addressed the issue of cancer immunotherapy activity with respect to tumor heterogeneity, with key topics addressing: 1) tumor heterogeneit…

0301 basic medicineOncologyTumor heterogeneitymedicine.medical_specialtymedicine.drug_classEndocrinology Diabetes and Metabolismmedicine.medical_treatmentImmunologyMonoclonal antibodyGeneral Biochemistry Genetics and Molecular BiologyTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicineImmune systemCancer immunotherapyInternal medicineImmunology and AllergyMedicineAnimalbusiness.industryMicrobiotaRepertoireMelanomaImmune checkpoints inhibitionAntibodies MonoclonalImmunotherapymedicine.diseaseCancer metabolismGastrointestinal MicrobiomeRadiation therapy030104 developmental biologyCancer stemness signaling030220 oncology & carcinogenesisNeoplasmImmunotherapybusinessHumanCytokine & Growth Factor Reviews
researchProduct

Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation

2017

MiR-29 family dysregulation occurs in various cancers including breast cancers. We investigated miR-29b-1 functional role in human triple negative breast cancer (TNBC) the most aggressive breast cancer subtype. We found that miR-29b-1-5p was downregulated in human TNBC tissues and cell lines. To assess whether miR- 29b-1-5p correlated with TNBC regenerative potential, we evaluated cancer stem cell enrichment in our TNBC cell lines, and found that only MDA-MB-231 and BT-20 produced primary, secondary and tertiary mammospheres, which were progressively enriched in OCT4, NANOG and SOX2 stemness genes. MiR-29b-1-5p expression inversely correlated with mammosphere stemness potential, and miR-29b…

0301 basic medicineOncologycancer stem cellsCarcinogenesisCell Cycle ProteinsTriple Negative Breast NeoplasmsMicroRNA 29b0302 clinical medicineCell MovementSettore BIO/10 - BiochimicaCancer stem cells; MiR-29b-1; SPIN1; Triple-negative breast cancer; Wnt/β-catenin and Akt signaling pathwaysMedicineBreastBreast -- CancerTriple-negative breast cancerWnt signaling pathwayMicroRNANanog Homeobox ProteinGene Expression Regulation NeoplasticOncologyWnt/β-catenin and Akt signaling pathway030220 oncology & carcinogenesisMiR-29b-1Wnt/β-catenin and Akt signaling pathwaysNeoplastic Stem Cellstriple-negative breast cancerFemaleMicrotubule-Associated ProteinsSignal TransductionResearch Papermedicine.medical_specialtycancer stem cellPaclitaxelDown-Regulation03 medical and health sciencesBreast cancerSOX2Cancer stem cellInternal medicineCell Line TumormicroRNAHumansNeoplasm InvasivenessCell ProliferationSPIN1business.industrySOXB1 Transcription Factorsmedicine.diseasePhosphoproteinsMolecular medicineAntineoplastic Agents PhytogenicMicroRNAs030104 developmental biologyDrug Resistance NeoplasmbusinessOctamer Transcription Factor-3
researchProduct

Role of the HIPPO pathway as potential key player in the cross talk between oncology and cardiology.

2021

The HIPPO pathway (HP) is a highly conserved kinase cascade that affects organ size by regulating proliferation, cell survival and differentiation. Discovered in Drosophila melanogaster to early 2000, it immediately opened wide frontiers in the field of research. Over the last years the field of knowledge on HP is quickly expanding and it is thought will offer many answers on complex pathologies. Here, we summarized the results of several studies that have investigated HP signaling both in oncology than in cardiology field, with an overview on future perspectives in cardiology research.

0301 basic medicineOncologymedicine.medical_specialtyCardiologyProtein Serine-Threonine KinasesCardiac regeneration03 medical and health sciences0302 clinical medicineInternal medicinemedicineAnimalsHumansHippo Signaling PathwayCardio oncologyCell survivalCell ProliferationHippo signaling pathwaybiologybusiness.industryHematologybiology.organism_classificationKinase cascade030104 developmental biologyDrosophila melanogasterOncologyCardiology fieldAnimals Cardiac development Cardiac regeneration Cardio-oncology Cardiology Cell Proliferation Drosophila melanogaster HIPPO signaling pathway Humans Protein Serine-Threonine Kinases030220 oncology & carcinogenesisCardiologyDrosophila melanogasterbusinessSignal TransductionCritical reviews in oncology/hematology
researchProduct

Systematic review and meta-analysis on targeted therapy in advanced pancreatic cancer

2015

Abstract Aim A systematic review and meta-analysis from literature has been performed to assess the impact of targeted therapy in advanced pancreatic cancer. Methods By searching different literature databases and major cancer meetings proceedings, data from all randomized clinical trials designed to investigate molecular targeted agents in the treatment of advanced pancreatic cancer were collected. The time-frame between January 2007 and March 2015 was selected. Data on predefined end-points, including overall survival, progression-free survival in terms of Hazard Ratio and response-rate were extracted and analyzed by a random effects model. Pooled data analysis was performed according to …

0301 basic medicineOncologymedicine.medical_specialtyFunnel plotEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic AgentsBioinformaticslaw.inventionTargeted therapy03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineGenetic Predisposition to DiseaseMeta-analysiAdvanced pancreatic cancerHepatologybusiness.industryHazard ratioGastroenterologyCancerPancreatic cancerPublication biasmedicine.diseasePancreatic NeoplasmsClinical trial030104 developmental biology030220 oncology & carcinogenesisMeta-analysisRandomized clinical trialbusinessSignal TransductionPathwayPancreatology
researchProduct